Piper Sandler on Structure Therapeutics (GPCR): 'We Continue to See GPCR as One of Our Best 2025 Ideas'
Tweet Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $93.00 price target on Structure Therapeutics (NASDAQ: GPCR).The analyst said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
